Quantitative evaluation of the efficacy and safety profiles of two types of targeted inhibitors combined with endocrine therapy in ER+/HER2− metastatic breast cancer.
Purpose: The aim of this study was to quantitatively compare the efficacy and safety of CDK4/6 inhibitors and PI3K/AKT/mTOR inhibitors for ER+/HER2− metastatic breast cancer. Methods: A parametric survival function was used to analyze the time course of overall survival (OS) and progression-free sur...
| Publicado en: | European Journal of Clinical Pharmacology Vol. 80; no. 9; pp. 1387 - 1398 |
|---|---|
| Autores principales: | , , , , |
| Formato: | equations & formulas research systematic review tables/charts Journal Article |
| Publicado: |
Springer Nature
Sep2024
|
| Acceso en línea: | Ver este registro en EBSCOhost |
| fields | @attributes: recordID: 1 pdfLink: plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=178855721&site=ehost-live header: @attributes: shortDbName: ccm uiTerm: 178855721 longDbName: CINAHL Complete uiTag: AN controlInfo: bkinfo: dissinfo: jinfo: jid: 00316970 NP9 jtl: European Journal of Clinical Pharmacology issn: 00316970 maglogo: N pubinfo: dt: Sep2024 vid: 80 iid: 9 pid: 237 pub: Springer Nature place: New York, New York artinfo: ui: 178855721 177981499 178855721 178855721 10.1007/s00228-024-03715-4 178855721 ppf: 1387 ppct: 11 formats: fmt: – @attributes: type: T – @attributes: type: P tig: atl: Quantitative evaluation of the efficacy and safety profiles of two types of targeted inhibitors combined with endocrine therapy in ER+/HER2− metastatic breast cancer. aug: au: Pan, Meiyu Lin, Yan Liu, Yinhui Xu, Ruijuan Yang, Jin affil: https://ror.org/01sfm2718 School of Pharmacy, China Pharmaceutical University, Nanjing, China sug: subj: Hormone Receptor Positive Breast Neoplasms Drug Therapy Neoplasm Metastasis Drug Therapy Drug Efficacy Patient Safety Antineoplastic Agents, Combined MTOR Inhibitors Therapeutic Use Cyclin-Dependent Kinases Antagonists and Inhibitors Phosphotransferases Antagonists and Inhibitors Antineoplastic Agents, Hormonal Therapeutic Use Human Meta Analysis Systematic Review Breast Neoplasms Prognosis Progression-Free Survival Treatment Outcomes Descriptive Statistics ab: Purpose: The aim of this study was to quantitatively compare the efficacy and safety of CDK4/6 inhibitors and PI3K/AKT/mTOR inhibitors for ER+/HER2− metastatic breast cancer. Methods: A parametric survival function was used to analyze the time course of overall survival (OS) and progression-free survival (PFS). The objective response rate (ORR) and the incidence of any grade and grade 3–4 adverse events were summarized using the random-effects model of a single-arm meta-analysis. Results: This study included 44 arms from 48 publications, with a total sample size of 7881 patients. Our study revealed that CDK4/6 inhibitors had a median OS of 40.7 months, a median PFS of 14.8 months, and an ORR of 40%, whereas PI3K/AKT/mTOR inhibitors had a median OS of 29.8 months, a median PFS of 8.3 months, and an ORR of 20%. Additionally, this study also found that the proportion of patients with visceral metastases and specific endocrine therapy used in combination significantly impact OS and PFS. In terms of adverse events, CDK4/6 inhibitors exhibited a relatively high incidence of hematological adverse events. Conclusion: Our study provides solid quantitative evidence for the first-line recommendation of CDK4/6 inhibitors combined with endocrine therapy for ER+/HER2− metastatic breast cancer in clinical guidelines. pubtype: Academic Journal doctype: equations & formulas meta analysis research systematic review tables/charts Journal Article ougenre: Article language: English refInfo: holdings: @attributes: islocal: N |
|---|